Trial Profile
Phase I Trial of Irinotecan (CPT-11) and Gemcitabine in Patients With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Irinotecan (Primary)
- Indications Bladder cancer; Breast cancer; Colorectal cancer; Lung cancer; Pancreatic cancer; Renal cancer
- Focus Adverse reactions
- 28 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2005 New trial record.